ASPCF News and Press, Acerus Pharmaceuticals Corp From 08/07/19

Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP; OTCQB:ASPCF) today reported its financial results for the three and six-month period ended June 30, 2019. Unless otherwise noted, all amounts are in US dollars and are prepared in accordance w...

U.S. market not affected   Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today announced that it will voluntarily replace certain NATESTO ® lots released in the Canadian and South Korean markets, which is expected to cause temporary shortages in those market...

Final study results accepted for “Late Breaking Presentation” on October 16, 2019 Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today announced that the NATESTO ® Spermatogenesis Study results have been accepted for presentation as a “Late-Bre...

Thinly traded nano cap Aytu BioScience (NASDAQ: AYTU ) is up  9%  premarket on modestly higher volume in reaction to its expanded agreement with commercialization partner Acerus Pharmaceuticals ( OTCQB:ASPCF ). More news on: Aytu BioScience, Inc., Acerus Pharmaceuticals Corpora...

TORONTO , July 30, 2019 /PRNewswire/ -- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB: ASPCF) today announced that it will be taking an expanded role in the commercialization of NATESTO ® in the U.S. The company has entered into an amended and restated licensing agreement ...

Acerus Pharmaceuticals to launch U.S. specialty sales force of at least 25 representatives Combined effort expected to optimize resources and execution to accelerate sales Investor conference call Tuesday, July 30, 2019 at 4:30 PM ET   Acerus Pharmaceuticals Cor...

Acerus Pharmaceuticals Corporation (TSX:ASP; OTCQB:ASPCF) will announce its second quarter 2019 financial and operating results on Wednesday, August 7, 2019 before the market opens. The company will also host a conference call on Wednesday, August 7, 2019 at 8:30 a.m. Eastern Time. To acc...

NATESTO® Now Covered on Payer Plans Covering Over 6 Million U.S. Lives   Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) (“Acerus” or the “Company”) announced today that NATESTO ® (testosterone nasal gel) is now on formulary ...

Acerus Pharmaceuticals ( OTCQB:ASPCF ) has entered into a $5M subordinated secured term loan facility with First Generation Capital Inc. More news on: Acerus Pharmaceuticals Corporation, Healthcare stocks news, Read more ...

Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP, OTCQB:ASPCF) today announced that it has entered into a US$5 million subordinated secured term loan facility (“the Loan”) with First Generation Capital Inc. (“First Genera...